Study on impact of bevacizumab combined with chemotherapy on therapeutic effect and quality of life in patients with non-small cell lung cancer
Objective To study the impact of bevacizumab combined with chemotherapy on effect and quality of life in patients with non-small cell lung cancer. Methods 80 patients with non-small cell lung cancer were selected and divided into a control group (n=40,chemotherapy) and a study group (n=40,bevacizumab+chemotherapy) according to odd-even number method. Patients in both groups were compared in terms of treatment effect,occurrence of adverse reactions,serum indicators (carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment),immune function indicators (immunoglobulin A,immunoglobulin G,immunoglobulin M),growth factors (basic fibroblast growth factor,vascular endothelial growth factor) and quality of life score before and after treatment. Results The effective rate of 75.00％ in the study group was higher than 52.50％ in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). After treatment,the carcinoembryonic antigen,carbohydrate antigen 125,and cytokeratin 19 fragment in both groups were lower than those before treatment in this group;in the study group,the carcinoembryonic antigen was (48.54±5.15) ng/ml,the carbohydrate antigen 125 was (62.24±5.31) U/ml,and the cytokeratin 19 fragment was (7.11±1.01) ng/ml,which were lower than (64.35±7.81) ng/ml,(70.65±6.87) U/ml,and (8.65±1.11) ng/ml in the control group (P<0.05). After treatment,the immunoglobulin A,immunoglobulin G and immunoglobulin M in both groups were lower than those before treatment in this group;in the study group,the immunoglobulin A was (1.57±0.21) g/L,the immunoglobulin G was (9.18±0.91) g/L,and the immunoglobulin M was (1.51±0.27) g/L,which were higher than (1.23±0.19),(8.24±0.89),and (1.25±0.25) g/L in the control group (P<0.05). After treatment,the basic fibroblast growth factor and vascular endothelial growth factor in both groups were lower than those before treatment in this group;in the study group,the basic fibroblast growth factor was (13.15±1.05) ng/L and the vascular endothelial growth factor was (254.24±15.38) ng/L,which were lower than (16.24±1.38) and (289.64±16.78) ng/L in the control group (P<0.05). After treatment,the quality of life score in both groups was lower than that before treatment in this group;the quality of life score of (33.15±1.05) points in the study group was lower than (38.54±1.45) points in the control group (P<0.05). Conclusion The combination of chemotherapy and bevacizumab has a remarkable effect in the treatment of patients with non-small cell lung cancer.
Non-small cell lung cancerBevacizumabChemotherapyTherapeutic effectQuality of life
万方数据
维普
